Comparison of Moisturizing Creams for the Prevention of Atopic Dermatitis Relapse : A Randomized Double-blind Controlled Multicentre Clinical Trial
| Autor: | Mats Grände, Petra Skare, Sakari Reitamo, Lisbeth Rustad, Tor Langeland, Karin Wiren, Mats Berg, Ulf Åkerström, Laura Korhonen, M Lodén, Åke Svensson |
|---|---|
| Přispěvatelé: | Department of Dermatology, Allergology and Venereology, Clinicum |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_treatment atopic eczema CHILDREN Kaplan-Meier Estimate SUSCEPTIBILITY Severity of Illness Index law.invention ECZEMATOUS SKIN Randomized controlled trial prevention law Recurrence Dry skin Secondary Prevention Prospective Studies Prospective cohort study skin and connective tissue diseases Aged 80 and over Cross-Over Studies atopic dermatitis Hazard ratio digestive oral and skin physiology food and beverages General Medicine Atopic dermatitis Middle Aged 3. Good health Dermatology and Venereal Diseases Treatment Outcome Female Moisturizer medicine.symptom Adult medicine.medical_specialty Adolescent Dermatology urea Administration Cutaneous Risk Assessment SKIN BARRIER FUNCTION Dermatitis Atopic Young Adult Double-Blind Method medicine Humans Aged Proportional Hazards Models Sweden moisturizer business.industry medicine.disease Crossover study emollients Clinical trial DRY SKIN 3121 General medicine internal medicine and other clinical medicine Quality of Life Dermatologic Agents business Follow-Up Studies |
| Zdroj: | Acta Dermato-Venereologica; 95(5), pp 587-592 (2015) |
| ISSN: | 1651-2057 |
| Popis: | Atopic dermatitis (AD) affects adults and children and has a negative impact on quality of life. The present multicentre randomized double-blind controlled trial showed a barrier-improving cream (5% urea) to be superior to a reference cream in preventing eczema relapse in patients with AD (hazard ratio 0.634, p = 0.011). The risk of eczema relapse was reduced by 37% (95% confidence interval (95% CI) 10-55%). Median time to relapse in the test cream group and in the reference cream group was 22 days and 15 days, respectively (p = 0.013). At 6 months 26% of the patients in the test cream group were still eczema free, compared with 10% in the reference cream group. Thus, the barrier-improving cream significantly prolonged the eczema-free time compared with the reference cream and decreased the risk of eczema relapse. The test cream was well tolerated in patients with AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|